Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Genmab Logo
Genmab Growth Score
69
CB Rank
11664
Heat Score
63
Genmab is a biotechnology company developing antibody-based therapies for cancer and other diseases.potential treatment of cancer.
Founded
obfuscation
PublicPost-IPO Debt Copenhagen, Hovedstaden, Denmark1001-5000 www.genmab.com
Biotechnology
Health Care
Manufacturing
Medical
Overview

Genmab
Total Funding
obfuscation
Growth Score
69
Heat Score
63

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score69
-17 pts
in past quarter
Heat Score 63
8 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Genmab

CB Rank
11664
Genmab is a biotechnology company developing antibody-based therapies for cancer and other diseases.potential treatment of cancer.
Founded
obfuscation
PublicPost-IPO Debt Copenhagen, Hovedstaden, Denmark1001-5000 www.genmab.com
Biotechnology
Health Care
Manufacturing
Medical

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Genmab A/S
Operating Status Active
Number of Exits 
obfuscation
Stock Symbol  CPH:GEN
Company Type For Profit
Founders  Don Drakeman
About the Company
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Its discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs.
Phone Number + 45 7020 2728
Contact Email info@genmab.com
Predictions & Insights

Growth Insight

See this Growth Insight
Genmab is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Rinatabart Sesutecan (Rina-S)
An investigational antibody therapeutic showing promising anti-tumor activity in heavily pretreated patients with ovarian and endometrial cancers.
AI-Powered Drug Discovery
Utilizes artificial intelligence to streamline the process of target identification and product candidate design for innovative antibody therapeutics.

Research & Development

Genmab is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
obfuscation
— Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Morgan Stanley Senior Funding Logo
Morgan Stanley Senior Funding
Yes
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
Morgan Stanley Senior Funding Logo
Morgan Stanley Senior Funding
Yes
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
Morgan Stanley Senior Funding Logo
Morgan Stanley Senior Funding
Yes
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
Morgan Stanley Senior Funding Logo
Morgan Stanley Senior Funding
Yes
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—
Morgan Stanley Senior Funding Logo
Morgan Stanley Senior Funding
Yes
Post-IPO Debt - Genmab Logo
Post-IPO Debt - Genmab
—

Investments

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 2
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation

Investment Breakdown

Number of Investments 1
Number of Exits 
obfuscation
Number of Acquisitions 2
See investment data for this company, with details on deal size, industry, stage, and more.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
obfuscation
Bolt Biotherapeutics Logo
Bolt Biotherapeutics
No
Post-IPO Equity - Bolt Biotherapeutics Logo
Post-IPO Equity - Bolt Biotherapeutics
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 1001-5000 Employee Profiles 16 Board Members and Advisors 2 Contacts 874

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jul 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 10, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

86,098
65.53%
 in past month

IT Spend

$70.8MThis year, Genmab is projected to spend $70.8M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Remnant Inventory Logo
Remnant Inventory
100
Telemedicine Logo
Telemedicine
100
Ad Copy Logo
Ad Copy
100

Actively Used Products

16Genmab uses 16 technology products and services including HTML5, Symantec Email Security.Cloud, and  Office 365, according to G2 Stack.

Active Website Tech Count

49Genmab is actively using 49 technologies for its website, according to BuiltWith. These include Mobile Non Scaleable Content, Google Cloud, and  Google.

Total IP

322The intellectual property of Genmab includes 254 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Genmab has registered 68 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Genmab's headquarters? Genmab is located in Copenhagen, Hovedstaden, Denmark.Who invested in Genmab? Genmab has 7 investors including Morgan Stanley Senior Funding and  GlaxoSmithKline.When was the last funding round for Genmab? Genmab closed its last funding round on
obfuscation
from a Post-IPO Debt round.How much funding has Genmab raised to date? Genmab has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(f7db04b 1)
|